144 related articles for article (PubMed ID: 17332320)
21. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
[TBL] [Abstract][Full Text] [Related]
22. Mutation of a Shc binding site tyrosine residue in ErbB3/HER3 blocks heregulin-dependent activation of mitogen-activated protein kinase.
Vijapurkar U; Cheng K; Koland JG
J Biol Chem; 1998 Aug; 273(33):20996-1002. PubMed ID: 9694850
[TBL] [Abstract][Full Text] [Related]
23. Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors.
Camenisch TD; Schroeder JA; Bradley J; Klewer SE; McDonald JA
Nat Med; 2002 Aug; 8(8):850-5. PubMed ID: 12134143
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
Sutterlüty H; Mayer CE; Setinek U; Attems J; Ovtcharov S; Mikula M; Mikulits W; Micksche M; Berger W
Mol Cancer Res; 2007 May; 5(5):509-20. PubMed ID: 17510316
[TBL] [Abstract][Full Text] [Related]
26. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
Sliwkowski MX; Schaefer G; Akita RW; Lofgren JA; Fitzpatrick VD; Nuijens A; Fendly BM; Cerione RA; Vandlen RL; Carraway KL
J Biol Chem; 1994 May; 269(20):14661-5. PubMed ID: 7514177
[TBL] [Abstract][Full Text] [Related]
27. Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation.
Sun CK; Man K; Ng KT; Ho JW; Lim ZX; Cheng Q; Lo CM; Poon RT; Fan ST
Carcinogenesis; 2008 Nov; 29(11):2096-105. PubMed ID: 18765415
[TBL] [Abstract][Full Text] [Related]
28. N-Glycosylation of the human kappa opioid receptor enhances its stability but slows its trafficking along the biosynthesis pathway.
Li JG; Chen C; Liu-Chen LY
Biochemistry; 2007 Sep; 46(38):10960-70. PubMed ID: 17711303
[TBL] [Abstract][Full Text] [Related]
29. Sprouty2 downregulation plays a pivotal role in mediating crosstalk between TGF-beta1 signaling and EGF as well as FGF receptor tyrosine kinase-ERK pathways in mesenchymal cells.
Ding W; Shi W; Bellusci S; Groffen J; Heisterkamp N; Minoo P; Warburton D
J Cell Physiol; 2007 Sep; 212(3):796-806. PubMed ID: 17516543
[TBL] [Abstract][Full Text] [Related]
30. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells.
Ueno Y; Sakurai H; Tsunoda S; Choo MK; Matsuo M; Koizumi K; Saiki I
Int J Cancer; 2008 Jul; 123(2):340-347. PubMed ID: 18398842
[TBL] [Abstract][Full Text] [Related]
31. Quantification of ErbB3 receptor density on human breast cancer cells, using a stable radio-labeled mutant of NRG1beta.
van der Woning SP; van Zoelen EJ
Biochem Biophys Res Commun; 2009 Jan; 378(2):285-9. PubMed ID: 19026613
[TBL] [Abstract][Full Text] [Related]
32. Tetraspanin CD151 impairs heterodimerization of ErbB2/ErbB3 in breast cancer cells.
Mieszkowska M; Piasecka D; Potemski P; Debska-Szmich S; Rychlowski M; Kordek R; Sadej R; Romanska HM
Transl Res; 2019 May; 207():44-55. PubMed ID: 30639369
[TBL] [Abstract][Full Text] [Related]
33. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
Huang X; Gao L; Wang S; Lee CK; Ordentlich P; Liu B
Cancer Res; 2009 Nov; 69(21):8403-11. PubMed ID: 19826038
[TBL] [Abstract][Full Text] [Related]
34. Requirement of protein kinase type I for cAMP-mediated up-regulation of lipid-linked oligosaccharide for asparagine-linked protein glycosylation.
Banerjee DK
Cell Mol Biol (Noisy-le-grand); 2007 May; 53(3):55-63. PubMed ID: 17531150
[TBL] [Abstract][Full Text] [Related]
35. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
Jani JP; Finn RS; Campbell M; Coleman KG; Connell RD; Currier N; Emerson EO; Floyd E; Harriman S; Kath JC; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Ralston S; Rossi AM; Steyn SJ; Wagner L; Winter SM; Bhattacharya SK
Cancer Res; 2007 Oct; 67(20):9887-93. PubMed ID: 17942920
[TBL] [Abstract][Full Text] [Related]
36. EGF receptor signalling is essential for electric-field-directed migration of breast cancer cells.
Pu J; McCaig CD; Cao L; Zhao Z; Segall JE; Zhao M
J Cell Sci; 2007 Oct; 120(Pt 19):3395-403. PubMed ID: 17881501
[TBL] [Abstract][Full Text] [Related]
37. A role for SHPS-1/SIRPalpha in Concanavalin A-dependent production of MMP-9.
Ruhul Amin AR; Uddin Biswas MH; Senga T; Feng GS; Kannagi R; Agarwal ML; Hamaguchi M
Genes Cells; 2007 Sep; 12(9):1023-33. PubMed ID: 17825046
[TBL] [Abstract][Full Text] [Related]
38. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells.
Kim KK; Lee JJ; Yang Y; You KH; Lee JH
Carcinogenesis; 2008 Apr; 29(4):704-12. PubMed ID: 18258606
[TBL] [Abstract][Full Text] [Related]
39. Conjugated linoleic acid inhibits cell proliferation and ErbB3 signaling in HT-29 human colon cell line.
Cho HJ; Kim WK; Kim EJ; Jung KC; Park S; Lee HS; Tyner AL; Park JH
Am J Physiol Gastrointest Liver Physiol; 2003 Jun; 284(6):G996-1005. PubMed ID: 12571082
[TBL] [Abstract][Full Text] [Related]
40. A mutated cathepsin-D devoid of its catalytic activity stimulates the growth of cancer cells.
Glondu M; Coopman P; Laurent-Matha V; Garcia M; Rochefort H; Liaudet-Coopman E
Oncogene; 2001 Oct; 20(47):6920-9. PubMed ID: 11687971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
